Tango Therapeutics (TNGX)
Tango Therapeutics on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, financials, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
44.8M
Short interest
settlement 2026-10-15
11.2
Days to cover
-1.4 days vs prior
37.6%
Short share of volume
2026-11-03
159,538
Fails to deliver
settlement 2026-10-01
Thu 7 Jan
Next earnings
estimated date
-$1.5M
Insider flow, 90 days
0 buys, 6 sells
As of 2026-11-03.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in TNGX is 44,777,592 shares, up 2,904,780 shares over the last month. Over the last 48 readings it ranged from 5,441,461 shares (31 January 2025) to 48,739,116 shares (27 February 2026). The latest reading sits at the top of that range. At the reported average volume of 4.0M shares a day that is 11.2 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/tngx" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 44,777,592 | +0.6% | 4,011,333 | 11.16 |
| 2026-09-30 | 44,500,110 | +6.3% | 3,547,777 | 12.54 |
| 2026-09-15 | 41,872,812 | -1.8% | 2,232,336 | 18.76 |
| 2026-08-31 | 42,627,550 | -1.3% | 2,163,725 | 19.70 |
| 2026-08-14 | 43,186,169 | -3.2% | 2,063,174 | 20.93 |
| 2026-07-31 | 44,608,423 | +4.4% | 2,329,361 | 19.15 |
| 2026-07-15 | 42,720,390 | +1.7% | 2,788,104 | 15.32 |
| 2026-06-30 | 42,009,250 | +23.4% | 6,375,825 | 6.59 |
| 2026-06-15 | 34,040,485 | +1.6% | 6,265,434 | 5.43 |
| 2026-05-29 | 33,488,854 | +5.3% | 2,573,472 | 13.01 |
| 2026-05-15 | 31,809,897 | -16.8% | 3,180,940 | 10.00 |
| 2026-04-30 | 38,250,843 | -5.0% | 3,058,423 | 12.51 |
| 2026-04-15 | 40,245,058 | -0.3% | 2,802,818 | 14.36 |
| 2026-03-31 | 40,370,279 | -14.6% | 3,339,110 | 12.09 |
| 2026-03-13 | 47,246,429 | -3.1% | 4,833,648 | 9.77 |
| 2026-02-27 | 48,739,116 | +3.6% | 2,677,862 | 18.20 |
| 2026-02-13 | 47,035,092 | +2.6% | 2,900,748 | 16.21 |
| 2026-01-30 | 45,822,083 | +7.2% | 2,730,190 | 16.78 |
| 2026-01-15 | 42,753,576 | +7.0% | 3,554,339 | 12.03 |
| 2025-12-31 | 39,972,307 | +19.1% | 2,963,418 | 13.49 |
| 2025-12-15 | 33,549,991 | +0.9% | 2,060,318 | 16.28 |
| 2025-11-28 | 33,248,529 | +7.9% | 3,349,512 | 9.93 |
| 2025-11-14 | 30,816,336 | +4.9% | 2,981,092 | 10.34 |
| 2025-10-31 | 29,388,713 | -19.1% | 5,509,303 | 5.33 |
| 2025-10-15 | 36,347,898 | +7.5% | 2,096,607 | 17.34 |
| 2025-09-30 | 33,812,698 | +26.2% | 3,350,182 | 10.09 |
| 2025-09-15 | 26,798,166 | +5.5% | 1,677,196 | 15.98 |
| 2025-08-29 | 25,400,631 | +1.0% | 1,357,773 | 18.71 |
| 2025-08-15 | 25,156,715 | +11.9% | 1,879,711 | 13.38 |
| 2025-07-31 | 22,475,890 | +4.4% | 1,712,325 | 13.13 |
| 2025-07-15 | 21,525,555 | +1.6% | 1,676,109 | 12.84 |
| 2025-06-30 | 21,193,333 | +35.3% | 3,517,634 | 6.02 |
| 2025-06-13 | 15,669,874 | -1.8% | 4,553,507 | 3.44 |
| 2025-05-30 | 15,954,703 | +16.0% | 6,358,239 | 2.51 |
| 2025-05-15 | 13,754,225 | +9.6% | 665,788 | 20.66 |
| 2025-04-30 | 12,554,952 | +11.7% | 580,353 | 21.63 |
| 2025-04-15 | 11,238,810 | +11.9% | 683,966 | 16.43 |
| 2025-03-31 | 10,042,724 | +10.2% | 805,898 | 12.46 |
| 2025-03-14 | 9,113,933 | +29.5% | 854,289 | 10.67 |
| 2025-02-28 | 7,036,859 | +18.4% | 771,908 | 9.12 |
| 2025-02-14 | 5,942,526 | +9.2% | 633,912 | 9.37 |
| 2025-01-31 | 5,441,461 | -22.5% | 617,186 | 8.82 |
| 2025-01-15 | 7,019,428 | -6.3% | 1,011,626 | 6.94 |
| 2024-12-31 | 7,493,267 | -7.1% | 1,425,267 | 5.26 |
| 2024-12-13 | 8,062,414 | +11.6% | 1,315,646 | 6.13 |
| 2024-11-29 | 7,222,311 | +1.6% | 1,549,099 | 4.66 |
| 2024-11-15 | 7,108,267 | -21.8% | 4,971,235 | 1.43 |
| 2024-10-31 | 9,084,727 | +2.0% | 1,143,327 | 7.95 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 3 November 2026, the short share of TNGX volume is 37.6%, down 30.3 points over the last five sessions. Over the last 30 readings it ranged from 35.1% (30 October 2026) to 84.7% (6 October 2026). The latest reading sits at the bottom of that range. The latest reading is 20.5 points below the 30-session average of 58.0%, on 871K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-03 | 327K | 871K | 37.6% | 550 |
| 2026-11-02 | 504K | 1.1M | 45.4% | 3,100 |
| 2026-10-30 | 870K | 2.5M | 35.1% | 47,478 |
| 2026-10-29 | 752K | 1.5M | 49.6% | 0 |
| 2026-10-28 | 761K | 1.4M | 55.5% | 2,300 |
| 2026-10-27 | 869K | 1.3M | 67.9% | 2,501 |
| 2026-10-26 | 1.2M | 2.4M | 50.1% | 27,023 |
| 2026-10-23 | 3.9M | 6.7M | 58.1% | 176,347 |
| 2026-10-22 | 1.9M | 2.8M | 66.9% | 1,511 |
| 2026-10-21 | 1.4M | 2.7M | 51.1% | 2,930 |
| 2026-10-20 | 465K | 939K | 49.5% | 0 |
| 2026-10-19 | 391K | 801K | 48.8% | 2,003 |
| 2026-10-16 | 873K | 1.7M | 52.9% | 8,212 |
| 2026-10-15 | 904K | 1.3M | 70.3% | 9,000 |
| 2026-10-14 | 1.3M | 1.7M | 78.0% | 1,000 |
| 2026-10-13 | 1.8M | 2.8M | 65.5% | 0 |
| 2026-10-12 | 749K | 1.2M | 62.3% | 900 |
| 2026-10-09 | 959K | 1.3M | 74.2% | 2,000 |
| 2026-10-08 | 923K | 2.2M | 42.2% | 2,000 |
| 2026-10-07 | 739K | 1.4M | 54.4% | 2,000 |
| 2026-10-06 | 1.9M | 2.3M | 84.7% | 2,602 |
| 2026-10-05 | 490K | 691K | 70.9% | 0 |
| 2026-10-02 | 1.4M | 2.7M | 50.0% | 1 |
| 2026-10-01 | 863K | 1.1M | 79.0% | 411 |
| 2026-09-30 | 752K | 1.4M | 55.4% | 3,300 |
| 2026-09-29 | 586K | 1.2M | 47.0% | 1,000 |
| 2026-09-28 | 413K | 1.0M | 39.8% | 3,000 |
| 2026-09-25 | 665K | 1.4M | 48.4% | 1,000 |
| 2026-09-24 | 597K | 781K | 76.4% | 800 |
| 2026-09-23 | 1.3M | 1.7M | 74.0% | 2 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 1 October 2026, the fails-to-deliver balance in TNGX is 159,538 shares, up 156,601 shares over the last settlement date. Over the last 30 readings it ranged from 1 share (25 August 2026) to 491,105 shares (24 September 2026).
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-10-01 | 159,538 | $24.95 | $4.0M |
| 2026-09-30 | 2,937 | $24.42 | $72K |
| 2026-09-29 | 2,251 | $24.30 | $55K |
| 2026-09-28 | 1 | $24.92 | $25 |
| 2026-09-24 | 491,105 | $24.45 | $12.0M |
| 2026-09-08 | 22,289 | $22.52 | $502K |
| 2026-08-25 | 1 | $24.51 | $25 |
| 2026-08-24 | 1,764 | $23.88 | $42K |
| 2026-08-20 | 67 | $25.20 | $2K |
| 2026-08-11 | 94,580 | $27.67 | $2.6M |
| 2026-08-10 | 97,667 | $27.07 | $2.6M |
| 2026-08-06 | 1,079 | $28.79 | $31K |
| 2026-08-03 | 4,576 | $27.18 | $124K |
| 2026-07-29 | 227,976 | $26.65 | $6.1M |
| 2026-07-27 | 303 | $26.63 | $8K |
| 2026-07-23 | 412 | $28.10 | $12K |
| 2026-07-16 | 149,777 | $30.25 | $4.5M |
| 2026-07-09 | 915 | $30.64 | $28K |
| 2026-07-08 | 1,132 | $30.12 | $34K |
| 2026-07-01 | 218,350 | $31.26 | $6.8M |
| 2026-06-30 | 3,694 | $32.56 | $120K |
| 2026-06-29 | 19 | $31.47 | $598 |
| 2026-06-25 | 63,928 | $29.12 | $1.9M |
| 2026-06-11 | 24,248 | $28.68 | $695K |
| 2026-06-10 | 516 | $31.56 | $16K |
| 2026-06-05 | 58,441 | $22.15 | $1.3M |
| 2026-05-29 | 16,358 | $20.00 | $327K |
| 2026-05-20 | 76,066 | $20.30 | $1.5M |
| 2026-05-19 | 50 | $20.63 | $1K |
| 2026-05-18 | 11 | $20.56 | $226 |
Insider trades
SEC Form 4, newest first. JSONInsiders at TNGX reported 6 open-market sells worth $1.5M in the last 90 days and no open-market buys. Latest filing: Crystal Adam (President, R&D) on 2026-10-01.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-10-01 | Crystal Adam | President, R&D | Sell | 600 | $25.32 | $15K | 116K |
| 2026-10-01 | Crystal Adam | President, R&D | Sell | 26K | $24.45 | $646K | 116K |
| 2026-10-01 | Crystal Adam | President, R&D | Exercise or conversion | 27K | $5.20 | $140K | 143K |
| 2026-09-22 | Newcomb Jessica | Principal Accounting Officer | Sell | 2K | $25.17 | $60K | 59K |
| 2026-09-22 | Newcomb Jessica | Principal Accounting Officer | Sell | 5K | $23.97 | $122K | 62K |
| 2026-09-22 | Newcomb Jessica | Principal Accounting Officer | Sell | 700 | $22.80 | $16K | 67K |
| 2026-09-01 | Crystal Adam | President, R&D | Sell | 27K | $22.37 | $604K | 116K |
| 2026-09-01 | Crystal Adam | President, R&D | Exercise or conversion | 27K | $5.20 | $140K | 143K |
| 2026-08-03 | Crystal Adam | President, R&D | Sell | 22K | $27.35 | $594K | 116K |
| 2026-08-03 | Crystal Adam | President, R&D | Sell | 5K | $26.79 | $141K | 137K |
| 2026-08-03 | Crystal Adam | President, R&D | Exercise or conversion | 27K | $5.20 | $140K | 143K |
| 2026-07-01 | Crystal Adam | President, R&D | Sell | 7K | $30.25 | $223K | 116K |
| 2026-07-01 | Crystal Adam | President, R&D | Sell | 20K | $29.34 | $576K | 123K |
| 2026-07-01 | Crystal Adam | President, R&D | Exercise or conversion | 27K | $5.20 | $140K | 143K |
| 2026-06-19 | Azelby Robert | Director | Grant | 6K | $0.00 | $0 | 6K |
| 2026-06-05 | Rothenberg Mace | Director | Grant | 4K | $0.00 | $0 | 42K |
| 2026-06-05 | Lee Sung | Director | Grant | 570 | $0.00 | $0 | 23K |
| 2026-06-05 | Ketchum John B | Director | Grant | 4K | $0.00 | $0 | 25K |
| 2026-06-05 | Calhoun Lesley Ann | Director | Grant | 4K | $0.00 | $0 | 17K |
| 2026-06-01 | Crystal Adam | President, R&D | Sell | 21K | $23.06 | $481K | 116K |
| 2026-06-01 | Crystal Adam | President, R&D | Sell | 6K | $22.25 | $137K | 137K |
| 2026-06-01 | Crystal Adam | President, R&D | Exercise or conversion | 27K | $5.20 | $140K | 143K |
| 2026-05-01 | Gall Matthew | Chief Financial Officer | Grant | 40K | $0.00 | $0 | 40K |
| 2026-05-01 | Crystal Adam | President, R&D | Sell | 1K | $22.00 | $24K | 116K |
| 2026-05-01 | Crystal Adam | President, R&D | Sell | 26K | $21.19 | $549K | 117K |
| 2026-05-01 | Crystal Adam | President, R&D | Exercise or conversion | 27K | $5.20 | $140K | 143K |
| 2026-04-29 | Lee Sung | Director | Grant | 12K | $0.00 | $0 | 22K |
| 2026-04-15 | Crystal Adam | President, R&D | Sell | 38K | $25.00 | $962K | 113K |
| 2026-04-15 | Crystal Adam | President, R&D | Exercise or conversion | 38K | $5.20 | $200K | 151K |
| 2026-04-01 | Crystal Adam | President, R&D | Sell | 27K | $21.20 | $572K | 113K |
| 2026-04-01 | Crystal Adam | President, R&D | Exercise or conversion | 27K | $5.20 | $140K | 140K |
| 2026-03-25 | Crystal Adam | President, R&D | Sell | 12K | $20.11 | $241K | 113K |
| 2026-03-25 | Crystal Adam | President, R&D | Exercise or conversion | 12K | $5.20 | $62K | 125K |
| 2026-03-05 | Crystal Adam | President, R&D | Sell | 20K | $15.00 | $304K | 113K |
| 2026-02-25 | Crystal Adam | President, R&D | Sell | 54K | $12.77 | $694K | 133K |
| 2026-02-03 | Weber Barbara | Director, Executive Chair | Sell | 333 | $12.90 | $4K | 1.6M |
| 2026-02-03 | Weber Barbara | Director, Executive Chair | Sell | 30K | $12.26 | $370K | 1.6M |
| 2026-02-03 | Crystal Adam | President, R&D | Sell | 201 | $12.90 | $3K | 187K |
| 2026-02-03 | Crystal Adam | President, R&D | Sell | 18K | $12.26 | $224K | 187K |
| 2026-02-03 | Beckman Daniella | Chief Financial Officer | Sell | 113 | $12.90 | $1K | 184K |
| 2026-02-03 | Beckman Daniella | Chief Financial Officer | Sell | 10K | $12.26 | $125K | 184K |
| 2026-02-02 | Weber Barbara | Director, Executive Chair | Grant | 38K | $0.00 | $0 | 1.7M |
| 2026-02-02 | Crystal Adam | President, R&D | Grant | 47K | $0.00 | $0 | 206K |
| 2026-02-02 | Beckman Daniella | Chief Financial Officer | Grant | 44K | $0.00 | $0 | 195K |
| 2026-01-08 | Peters Malte | President & CEO | Grant | 350K | $0.00 | $0 | 368K |
| 2026-01-02 | Lee Sung | Director | Grant | 10K | $0.00 | $0 | 10K |
| 2025-10-23 | TRV GP IV, LLC | TenPercentOwner | Sell | 477K | $10.15 | $4.8M | 13.4M |
| 2025-10-23 | Third Rock Ventures IV, L.P. | 10% owner | Sell | 477K | $10.15 | $4.8M | 13.4M |
| 2025-09-25 | TRV GP IV, LLC | TenPercentOwner | Sell | 500K | $8.02 | $4.0M | 13.9M |
| 2025-09-25 | Third Rock Ventures IV, L.P. | 10% owner | Sell | 500K | $8.02 | $4.0M | 13.9M |
| 2025-09-16 | TRV GP IV, LLC | TenPercentOwner | Sell | 364K | $7.04 | $2.6M | 14.4M |
| 2025-09-16 | Third Rock Ventures IV, L.P. | 10% owner | Sell | 364K | $7.04 | $2.6M | 14.4M |
| 2025-09-08 | TRV GP IV, LLC | TenPercentOwner | Sell | 86K | $7.04 | $609K | 14.7M |
| 2025-09-08 | Third Rock Ventures IV, L.P. | 10% owner | Sell | 86K | $7.04 | $609K | 14.7M |
| 2025-09-05 | TRV GP IV, LLC | TenPercentOwner | Sell | 643K | $7.00 | $4.5M | 14.8M |
| 2025-09-05 | Third Rock Ventures IV, L.P. | 10% owner | Sell | 643K | $7.00 | $4.5M | 14.8M |
| 2025-08-22 | Third Rock Ventures GP IV, L.P. | TenPercentOwner | Sell | 302K | $7.00 | $2.1M | 15.5M |
| 2025-08-22 | Third Rock Ventures IV, L.P. | 10% owner | Sell | 302K | $7.00 | $2.1M | 15.5M |
| 2025-08-19 | Third Rock Ventures GP IV, L.P. | TenPercentOwner | Sell | 1.1M | $7.01 | $7.7M | 15.8M |
| 2025-08-19 | Third Rock Ventures IV, L.P. | 10% owner | Sell | 1.1M | $7.01 | $7.7M | 15.8M |
| 2025-06-05 | Borisy Alexis | Director | Grant | 6K | $0.00 | $0 | 18K |
| 2025-06-05 | Ketchum John B | Director | Grant | 6K | $0.00 | $0 | 21K |
| 2025-06-05 | Rothenberg Mace | Director | Grant | 6K | $0.00 | $0 | 38K |
| 2025-06-05 | Calhoun Lesley Ann | Director | Grant | 6K | $0.00 | $0 | 13K |
| 2025-06-05 | Peters Malte | Director | Grant | 6K | $0.00 | $0 | 18K |
| 2025-02-05 | Weber Barbara | Chief Executive Officer | Sell | 9K | $3.16 | $28K | 1.6M |
| 2025-02-05 | Crystal Adam | See Remarks | Sell | 7K | $3.16 | $22K | 158K |
| 2025-02-05 | Beckman Daniella | Chief Financial Officer | Sell | 4K | $3.16 | $12K | 150K |
| 2025-02-05 | Barry Douglas | General Counsel | Sell | 3K | $3.16 | $8K | 66K |
| 2025-02-04 | Weber Barbara | Chief Executive Officer | Sell | 10K | $2.99 | $29K | 1.6M |
| 2025-02-04 | Crystal Adam | See Remarks | Sell | 7K | $2.99 | $22K | 165K |
| 2025-02-04 | Beckman Daniella | Chief Financial Officer | Sell | 4K | $2.99 | $13K | 154K |
| 2025-02-04 | Barry Douglas | General Counsel | Sell | 3K | $2.99 | $8K | 69K |
| 2025-02-03 | Barry Douglas | General Counsel | Grant | 27K | $0.00 | $0 | 71K |
| 2025-02-03 | Weber Barbara | Chief Executive Officer | Grant | 106K | $0.00 | $0 | 1.6M |
| 2025-02-03 | Crystal Adam | See Remarks | Grant | 53K | $0.00 | $0 | 172K |
| 2025-02-03 | Beckman Daniella | Chief Financial Officer | Grant | 26K | $0.00 | $0 | 159K |
| 2024-11-18 | Rothenberg Mace | Director | Buy | 10K | $3.78 | $38K | 31K |
| 2024-11-14 | Rothenberg Mace | Director | Buy | 10K | $3.62 | $36K | 21K |
| 2024-11-07 | EcoR1 Capital, LLC | TenPercentOwner | Sell | 1.1M | $2.92 | $3.3M | 10.6M |
| 2024-11-07 | EcoR1 Capital, LLC | TenPercentOwner | Sell | 62K | $3.29 | $205K | 11.8M |
| 2024-11-06 | Boxer Capital Management, LLC | Other | Sell | 3.1M | $3.14 | $9.7M | 3.6M |
| 2024-11-06 | EcoR1 Capital, LLC | TenPercentOwner | Sell | 1.5M | $3.28 | $4.9M | 11.8M |
| 2024-10-25 | Boxer Capital Management, LLC | Other | Sell | 633K | $6.87 | $4.3M | 6.7M |
| 2024-10-22 | Boxer Capital Management, LLC | Other | Sell | 250K | $6.78 | $1.7M | 7.3M |
| 2024-10-21 | Boxer Capital Management, LLC | Other | Sell | 625K | $7.05 | $4.4M | 7.6M |
| 2024-09-13 | TRV GP IV, LLC | TenPercentOwner | Sell | 67K | $10.53 | $710K | 16.9M |
| 2024-09-05 | TRV GP IV, LLC | TenPercentOwner | Sell | 75K | $11.56 | $867K | 16.9M |
| 2024-08-30 | Third Rock Ventures IV, L.P. | TenPercentOwner | Sell | 175K | $11.60 | $2.0M | 17.0M |
| 2024-08-27 | Third Rock Ventures IV, L.P. | TenPercentOwner | Sell | 25K | $11.55 | $289K | 17.2M |
| 2024-08-19 | Third Rock Ventures GP IV, L.P. | TenPercentOwner | Sell | 150K | $10.09 | $1.5M | 17.2M |
| 2024-08-16 | Third Rock Ventures GP IV, L.P. | TenPercentOwner | Sell | 135K | $9.79 | $1.3M | 17.4M |
| 2024-08-01 | Third Rock Ventures GP IV, L.P. | TenPercentOwner | Sell | 40K | $9.80 | $392K | 17.5M |
| 2024-07-31 | Third Rock Ventures GP IV, L.P. | TenPercentOwner | Sell | 100K | $9.93 | $993K | 17.5M |
| 2024-07-30 | Third Rock Ventures GP IV, L.P. | TenPercentOwner | Sell | 95K | $9.80 | $931K | 17.6M |
| 2024-07-26 | TRV GP IV, LLC | TenPercentOwner | Sell | 50K | $9.84 | $492K | 17.7M |
| 2024-07-25 | Third Rock Ventures IV, L.P. | TenPercentOwner | Sell | 101K | $9.87 | $993K | 17.8M |
| 2024-07-24 | Third Rock Ventures IV, L.P. | TenPercentOwner | Sell | 200K | $9.82 | $2.0M | 17.9M |
| 2024-07-23 | Third Rock Ventures GP IV, L.P. | TenPercentOwner | Sell | 125K | $9.79 | $1.2M | 18.1M |
| 2024-07-22 | Third Rock Ventures GP IV, L.P. | TenPercentOwner | Sell | 263K | $9.78 | $2.6M | 18.2M |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON13 Form 144 notices on file for TNGX worth $182.4M at the prices reported; 2 in the last 90 days worth $795K. Latest: ADAM CRYSTAL filed on 2026-11-02 to sell 20,000 shares ($454K) from 2026-11-02.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-11-02 | ADAM CRYSTALOfficer | 20K | $454K | 0.012% | 2026-11-02 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-09-22 | Jessica NewcombOfficer | 15K | $340K | 0.009% | 2026-09-22 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-08-03 | ADAM CRYSTALOfficer | 81K | $2.2M | 0.056% | 2026-08-03 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-17 | Nextech Crossover I SCSpFormer Affiliate | 3.8M | $113.4M | 2.604% | 2026-06-17 | Goldman Sachs & Co. LLC |
| 2026-06-11 | DANIELLA BECKMANOfficer | 1.8M | $51.5M | 1.239% | 2026-06-11 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-10 | DANIELLA BECKMANOfficer | 4K | $133K | 0.003% | 2026-06-10 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-05-01 | ADAM CRYSTALOfficer | 65K | $1.4M | 0.046% | 2026-05-01 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-03-25 | ADAM CRYSTALOfficer | 93K | $1.8M | 0.065% | 2026-03-25 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-03-05 | ADAM CRYSTALOfficer | 20K | $250K | 0.014% | 2026-03-05 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-02-25 | ADAM CRYSTALOfficer | 54K | $700K | 0.040% | 2026-02-25 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-10-23 | Third Rock Ventures IV, L.P.10% Stockholder | 477K | $3.6M | 0.361% | 2025-10-23 | BTIG, LLC |
| 2025-09-25 | Third Rock Ventures IV, L.P.10% Stockholder | 500K | $3.9M | 0.449% | 2025-09-25 | BTIG, LLC |
| 2025-09-17 | Third Rock Ventures IV, L.P.10% Stockholder | 364K | $2.7M | 0.327% | 2025-09-16 | BTIG, LLC |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first, 50 of 67 shown. JSON27 holders report 5% or more of TNGX in their latest filing, all on Schedule 13G (passive). The largest reported stake is TCG Crossover GP II, L.P. at 10.0% of the class (13,521,839 shares), filed 2026-02-17 for an event on 2025-12-31.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-08-14 | 13G/Ano. 2 | Nextech Crossover I GP S.a. r.l.other entity | 0 | 0.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Nextech Crossover I SCSppartnership | 0 | 0.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Ian Charoubindividual | 0 | 0.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Costas Constantinidesindividual | 0 | 0.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Rocco Sgobboindividual | 0 | 0.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 4 | TCG Crossover GP II, LLCother entity | 10.1M | 7.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 4 | TCG Crossover Fund II, L.P.partnership | 10.1M | 7.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 4 | Chen Yuindividual | 10.1M | 7.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 3 | Woodline Partners LPinvestment adviser, partnership | 4.0M | 2.5% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 5 | Dunn Hannah E.parent holding company, individual | 16.3M | 9.8% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 5 | Giauque, Nicolasparent holding company, individual | 16.3M | 9.8% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 5 | Husen, Avner A.parent holding company, individual | 16.3M | 9.8% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 5 | Kim, David T.parent holding company, individual | 16.3M | 9.8% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 5 | Linn, Michael G.parent holding company, individual | 16.3M | 9.8% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 5 | Luo Patrick (Cheng)parent holding company, individual | 16.3M | 9.8% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 5 | Roberts, Jr., Thomas G.parent holding company, individual | 16.3M | 9.8% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 5 | Saito Edric C.parent holding company, individual | 16.3M | 9.8% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 5 | Short Daniel S.parent holding company, individual | 16.3M | 9.8% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 5 | Spokes, Andrew J. M.parent holding company, individual | 16.3M | 9.8% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 5 | Warren, John R.parent holding company, individual | 16.3M | 9.8% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 5 | Wehrly, Mark C.parent holding company, individual | 16.3M | 9.8% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 5 | Farallon Capital Management, L.L.C.investment adviser, other entity | 16.3M | 9.8% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 5 | Dapice Joshua J.parent holding company, individual | 16.3M | 9.8% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 5 | Dreyfuss, Philip D.parent holding company, individual | 16.3M | 9.8% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 5 | Gehani, Varun N.parent holding company, individual | 16.3M | 9.8% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 5 | Farallon Healthcare Partners Master, L.P.partnership | 0 | 0.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 5 | Farallon Capital Partners, L.P.partnership | 0 | 0.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 5 | Farallon Capital Institutional Partners, L.P.partnership | 0 | 0.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 5 | Farallon Capital Institutional Partners II, L.P.partnership | 0 | 0.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 5 | Farallon Capital Institutional Partners III, L.P.partnership | 0 | 0.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 5 | Four Crossings Institutional Partners V, L.P.partnership | 0 | 0.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 5 | Farallon Capital Offshore Investors II, L.P.partnership | 0 | 0.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 5 | Farallon Capital (AM) Investors, L.P.partnership | 0 | 0.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 5 | Farallon Capital F5 Master I, L.P.partnership | 0 | 0.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 5 | Farallon Partners, L.L.C.other entity | 0 | 0.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 5 | Farallon Institutional (GP) V, L.L.C.other entity | 0 | 0.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 5 | Farallon F5 (GP), L.L.C.other entity | 0 | 0.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 5 | Farallon Healthcare Partners (GP), L.L.C.other entity | 0 | 0.0% | 2026-06-30 |
| 2026-08-14 | 13G | THE GOLDMAN SACHS GROUP, INC.parent holding company, corporation | 9.7M | 6.0% | 2026-06-30 |
| 2026-08-14 | 13G | GOLDMAN SACHS & CO. LLCbroker-dealer, other entity, investment adviser | 9.7M | 6.0% | 2026-06-30 |
| 2026-08-12 | 13G/Ano. 2 | Robert Atchinsonparent holding company, individual | 5.6M | 3.4% | 2026-06-30 |
| 2026-08-12 | 13G/Ano. 2 | Phillip Grossparent holding company, individual | 5.6M | 3.4% | 2026-06-30 |
| 2026-08-12 | 13G/Ano. 2 | Adage Capital Management, L.P.investment adviser, partnership | 5.6M | 3.4% | 2026-06-30 |
| 2026-05-15 | 13G | Roderick Wongparent holding company, individual | 13.3M | 9.3% | 2026-03-31 |
| 2026-05-15 | 13G | RTW Investments, LPinvestment adviser, partnership | 13.3M | 9.3% | 2026-03-31 |
| 2026-05-06 | 13G | FMR LLCparent holding company | 9.9M | 6.9% | 2026-03-31 |
| 2026-05-06 | 13G | Abigail P. Johnsonindividual | 9.9M | 6.9% | 2026-03-31 |
| 2026-05-04 | 13G/Ano. 2 | Raymond Debbaneindividual | 5.7M | 4.0% | 2026-03-31 |
| 2026-05-04 | 13G/Ano. 2 | Invus Global Management, LLCother entity | 5.0M | 3.5% | 2026-03-31 |
| 2026-05-04 | 13G/Ano. 2 | Invus Public Equities Advisors, LLCother entity | 5.0M | 3.5% | 2026-03-31 |
13F holders
Tracked managers holding TNGX at their latest 13F. JSON7 of the 30 tracked managers held TNGX at their latest 13F, $82.4M in total at quarter-end prices. Renaissance Technologies is the largest at $23.4M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 5 added shares and 2 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Renaissance Technologies | 2026-06-30 | 748K | $23.4M | 0.03% | new |
| Fisher Asset Management | 2026-06-30 | 578K | $18.1M | 0.01% | +416K |
| Millennium Management | 2026-06-30 | 496K | $15.5M | 0.01% | +70K |
| Point72 Asset Management | 2026-06-30 | 298K | $9.3M | 0.01% | -236K |
| Two Sigma Investments | 2026-06-30 | 242K | $7.6M | 0.01% | +69K |
| Citadel Advisors | 2026-06-30 | 181K | $5.7M | 0.00% | +2K |
| AQR Capital Management | 2026-06-30 | 91K | $2.8M | 0.00% | -16K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn Q2 FY 2026 (quarter ended 2026-06-30) Tango Therapeutics reported revenue of $0, down 100.0% from the same quarter a year earlier, and net loss of $55.3M (-0.37 diluted EPS). In FY 2025 it generated -$138.9M of operating cash flow.
- Cash
- $345.6M
- Equity
- $1.02B
- Total assets
- $1.07B
- Shares outstanding
- 168,610,367
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 FY 2026 | 2026-06-30 | $0 | -$55.3M | n/a | -0.37 |
| Q1 FY 2026 | 2026-03-31 | $0 | -$45.5M | n/a | -0.32 |
| Q4 FY 2025derived | 2025-12-31 | $0 | -$38.7M | n/a | n/a |
| Q3 FY 2025 | 2025-09-30 | $53.8M | $15.9M | 29.5% | 0.13 |
| Q2 FY 2025 | 2025-06-30 | $3.2M | -$38.9M | -1221.4% | -0.35 |
| Q1 FY 2025 | 2025-03-31 | $5.4M | -$39.9M | -739.5% | -0.36 |
| Q4 FY 2024derived | 2024-12-31 | $4.1M | -$37.7M | -915.2% | n/a |
| Q3 FY 2024 | 2024-09-30 | $11.6M | -$29.2M | -251.3% | -0.27 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $62.4M | -$101.6M | -$138.9M | $1.0M | n/a | n/a |
| FY 2024 | 2024-12-31 | $42.1M | -$130.3M | -$131.5M | $754K | n/a | n/a |
| FY 2023 | 2023-12-31 | $36.5M | -$101.7M | -$118.0M | $1.5M | n/a | n/a |
| FY 2022 | 2022-12-31 | $24.9M | -$108.2M | -$109.1M | $7.7M | n/a | n/a |
| FY 2021 | 2021-12-31 | $37.0M | -$58.2M | -$59.5M | $1.8M | n/a | n/a |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-08-04 from the cover page.
What this page is
Tango Therapeutics in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Tango Therapeutics (TNGX), SEC CIK 1819133, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-03.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-10-01.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-11-02.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-08-14.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-11.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-10-01.JSON and CSV
- Company record
- EDGAR filing index for CIK 1819133Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
Other company pages
Datasets
Frequently Asked Questions
How much of TNGX is sold short?
44,777,592 shares were held short at the 2026-10-15 settlement, 11.2 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is TNGX's daily short volume?
On 2026-11-03, 327,391 of the 871,247 TNGX shares reported to FINRA were sold short, 37.6% of the day's reported volume. Short volume is a flow for one day, not a position.
Does TNGX have fails to deliver?
The SEC's latest file shows 159,538 TNGX shares failed to deliver at settlement 2026-10-01. Fails are reported per settlement date and published twice a month with a lag.
Are TNGX insiders buying or selling?
Insiders at TNGX reported 6 open-market sells worth $1.5M in the last 90 days and no open-market buys. Latest filing: Crystal Adam (President, R&D) on 2026-10-01.
Have TNGX insiders filed to sell?
13 Form 144 notices on file for TNGX worth $182.4M at the prices reported; 2 in the last 90 days worth $795K. Latest: ADAM CRYSTAL filed on 2026-11-02 to sell 20,000 shares ($454K) from 2026-11-02.
Who owns 5% or more of TNGX?
27 holders report 5% or more of TNGX in their latest filing, all on Schedule 13G (passive). The largest reported stake is TCG Crossover GP II, L.P. at 10.0% of the class (13,521,839 shares), filed 2026-02-17 for an event on 2025-12-31.
What did TNGX report last quarter?
In Q2 FY 2026 (quarter ended 2026-06-30) Tango Therapeutics reported revenue of $0, down 100.0% from the same quarter a year earlier, and net loss of $55.3M (-0.37 diluted EPS). In FY 2025 it generated -$138.9M of operating cash flow.
Which tracked 13F managers own TNGX?
7 of the 30 tracked 13F managers held TNGX shares at their latest filing, $82.4M in all. The largest: Renaissance Technologies (748K shares, $23.4M), Ken Fisher's Fisher Asset Management (578K shares, $18.1M), Izzy Englander's Millennium Management (496K shares, $15.5M), Steve Cohen's Point72 Asset Management (298K shares, $9.3M), Two Sigma Investments (242K shares, $7.6M), Ken Griffin's Citadel Advisors (181K shares, $5.7M). The table above lists all 7.
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.